U.S. Markets closed

Takeda Pharmaceutical Company Limited (TKPHF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
54.0150.000 (0.000%)
At close: 11:12AM EDT
People also watch
TKPYYALPMFESALYESALFALPMY
Full screen
Previous Close54.015
Open0.000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume1,182
Market Cap42.06B
BetaN/A
PE Ratio (TTM)41.36
EPS (TTM)1.31
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Takeda Pharmaceutical Co., Ltd. – Value Analysis (US OTC:TKPHF) : August 14, 2017
    Capital Cube2 days ago

    Takeda Pharmaceutical Co., Ltd. – Value Analysis (US OTC:TKPHF) : August 14, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Takeda Pharmaceutical Co., Ltd. a score of 41. Our analysis is based on comparing Takeda Pharmaceutical Co., Ltd. with the following peers – Amgen Inc., GlaxoSmithKline plc Sponsored ADR, Novartis AG Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Pfizer Inc., Merck & Co., Inc., Johnson & ... Read more (Read more...)

  • Takeda Pharmaceutical Co., Ltd. breached its 50 day moving average in a Bullish Manner : TKPHF-US : July 31, 2017
    Capital Cube16 days ago

    Takeda Pharmaceutical Co., Ltd. breached its 50 day moving average in a Bullish Manner : TKPHF-US : July 31, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Takeda Pharmaceutical Co., Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • American City Business Journals20 days ago

    Waltham's Tesaro grabs $100M in cancer drug partnership with Takeda

    Waltham-based Tesaro is capitalizing on the early success of its new cancer drug, handing over some development and commercial rights to Takeda in a deal worth up to $340 million plus royalties. Tesaro (TSRO) said Thursday that the once-daily pill, which is marketed in the U.S. as Zejula following an FDA approval in March, will be developed and sold by Takeda in Japan, where the drug giant is headquartered. Under the deal, Takeda will get development and commercial rights in four additional countries — South Korea, Taiwan, Russia and Australia — for all kinds of tumors except prostate cancer.